TTrialPathMatch Me to Trials
← Back to trials
RecruitingPediatric ObesityType 2 Diabetes

Low EnerGy DiEt iN Adolescents With Obesity and Type 2 Diabetes: The LEGEND Study

Eligible age

12–17 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a multicentre, single-arm, feasibility study in adolescents with T2DM and obesity to investigate the recruitment and retention rates to a study using Low Energy Diets(LED). It will also provide estimates of weight loss needed to bring about remission to inform a larger randomised study. In addition a subgroup of participants and their parents/carers undertaking a period of LED will be interviewed to understand the participants experience of taking part. Two further groups will also be interviewed: participants and their parents/carers who have declined to take part in the LED to understand their motivations and barriers and healthcare practitioners who have participated in conducting the trial to understand their experience of the study.

Sponsor: Nottingham University Hospitals NHS Trust

You may qualify if…

  • LED intervention
  • Diagnosis of T2DM (defined as an HbA1C ≥48mmol/mol, in the absence of features of type 1 or monogenic/syndromic diabetes).
  • Current HbA1C ≥48 (or ≥42 on antidiabetic medication) and ≤ 80 mmol/mol.
  • Aged 12 to 17 years old.
  • BMI ≥98th centile (+2 SD) for age and sex (UK90 growth reference data).
  • Informed consent:
  • Received from the young person (age 16-17) OR
  • Received from young person's parent/carer, with patient assent (age 12-15).

You may not qualify if…

  • LED intervention
  • HbA1C greater than 80mmol/mol.
  • Presence of diabetes-related autoantibodies, as per local centre guidelines.
  • Confirmed mono-genetic cause of obesity (e.g. SIM1 mutation) or diabetes-associated syndrome such as Prader-Willi syndrome, Bardet-Biedl or Wolfram's syndrome.
  • Secondary diabetes (post bone marrow transplant/chemotherapy).
  • Significant psychiatric co-morbidity.
  • Breastfeeding, pregnant or planning to conceive during the LED and FR phases (female participants will be advised on need for effective contraceptive methods during the 12-month study period, section 5.1.1.10).
  • Any other condition which, in the opinion of the study investigator, would make it inappropriate to undertake a period of LED. (All reasons for not approaching patients will be recorded and analysed anonymously. Cases can be discussed with the core study group if there is doubt).

Source: ClinicalTrials.gov · NCT06572345 · last updated 2025-08-03